Verve Therapeutics, Inc.
VERV
$6.16
-$0.16-2.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -31.03M | -50.04M | -50.13M | -49.81M | -48.74M |
| Total Depreciation and Amortization | 1.72M | 1.70M | 1.75M | 1.67M | 1.63M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.92M | 10.34M | 9.89M | 8.23M | 8.06M |
| Change in Net Operating Assets | -9.45M | -2.85M | -1.12M | 5.75M | -4.04M |
| Cash from Operations | -27.85M | -40.85M | -39.61M | -34.16M | -43.08M |
| Capital Expenditure | -1.22M | -1.39M | -936.00K | -980.00K | -433.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -46.94M | 30.93M | 57.75M | 31.13M | -41.20M |
| Cash from Investing | -48.17M | 29.55M | 56.81M | 30.15M | -41.63M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7.00K | 25.22M | 14.00K | 1.25M | 22.79M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -66.00K | -- | 51.00K | -51.00K |
| Cash from Financing | 7.00K | 25.15M | 14.00K | 1.30M | 22.73M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -76.01M | 13.85M | 17.22M | -2.71M | -61.98M |